CanSino Bio issued an announcement on the 14th, saying that it has noticed some media reports about rare and severe cases of thrombosis in individuals after being vaccinated with AstraZeneca’s new crown vaccine and Johnson’s new crown vaccine. As of that day, about one million people vaccinated with CanSino Bio’s Ad5-nCoV new crown vaccine have not received reports of serious adverse events related to thrombosis.
CanSino Bio said that the recombinant new coronavirus vaccine (adenovirus type 5 vector) (Ad5-nCoV) developed by the company is type 5 adenovirus, which is a common adenovirus that infects humans. The chimpanzee adenovirus vector used in the vaccine is different from the type 26 adenovirus vector used in the Johnson & Johnson Covid-19 vaccine.
Before the announcement on the 14th, CanSino Bio’s share prices on Hong Kong stocks and the Science and Technology Innovation Board fell. Market analysis believes that this is affected by the “thrombosis problem” of AstraZeneca’s new crown vaccine and Johnson & Johnson’s new crown vaccine.
On the 13th local time, the Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) issued a joint statement suggesting that the Johnson & Johnson new crown vaccine should be suspended. Previously, six vaccinators in the United States had rare blood clots and had vaccinations. death. AstraZeneca’s new crown vaccine has been turbulent before due to thrombosis, and it has been banned in many countries.